|
| | Etofenamate Basic information |
| Product Name: | Etofenamate | | Synonyms: | EtofenamateEtofenamate;2-(2-hydroxyaethoxy)aethylester der flutenaminsaeure;2-(2-hydroxyethoxy)ethyl-n-(alpha,alpha,alpha-trifluoro-m-tolyl)anthrani late;Benzoic acid, 2[[3-(trifluoromethyl)phenyl]amino]-2-(hydroxyethoxy)ethyl ester;n-(alpha,alpha,alpha-trifluoro-m-tolyl)-anthranilic acid 2-(2-hydroxyethoxy);2-(2-Hydroxyethoxy)ethyl 2-[3-(trifluoromethyl)anilino]benzoate;Ethofenamate;Rheumon | | CAS: | 30544-47-9 | | MF: | C18H18F3NO4 | | MW: | 369.33 | | EINECS: | 250-231-8 | | Product Categories: | Inhibitors;Amines;Aromatics;Intermediates & Fine Chemicals;Pharmaceuticals | | Mol File: | 30544-47-9.mol |  |
| | Etofenamate Chemical Properties |
| Melting point | 25°C | | Boiling point | bp.001 130-135° | | density | 1.2866 (estimate) | | refractive index | nD25 1.564 | | storage temp. | Sealed in dry,2-8°C | | solubility | Practically insoluble in water, miscible with ethanol (96 per cent) and with ethyl acetate. | | form | neat | | pka | 14.32±0.10(Predicted) | | Stability: | Light Sensitive |
| RIDADR | UN2810 - class 6.1 - PG 3 - EHS - Toxic, liquids, organic, n.o.s., HI: all | | Toxicity | LD50 in male, female rats (mg/kg): 292, 470 orally; 140, 226 i.v.; 373, 397 i.p.; 643, 568 s.c. (Jacobi) |
| | Etofenamate Usage And Synthesis |
| Chemical Properties | Light Yellow Oil | | Originator | Rheumon,Troponwerke,W. Germany,1977 | | Uses | As a histamine H1 -receptor antagonist, Etofenamate can be used as anti-inflammatory;cyclooxygenase inhibitor and medication used to alleviate joint and muscle pain.
| | Definition | ChEBI: 2-[3-(trifluoromethyl)anilino]benzoic acid 2-(2-hydroxyethoxy)ethyl ester is a benzoate ester. | | Manufacturing Process | 16.0 g (0.05 mol) of the potassium salt of N-(3-trifluoromethylphenyl)-
anthranilic acid are dissolved in 60 ml of dimethylformamide and heated to
110°C, and 6.2 g (0.05 mol) of 2-(2-chloroethoxy)-ethanol are slowly added.
The reaction mixture is then heated to boiling for 2 hours. The precipitated
potassium chloride is filtered off and the solvent is removed by evaporation.
The residue is separated over a column with 400 g of silica gel (particle size
0.05 to 0.2 mm), using a 1:1 mixture of cyclohexane and glacial acetic acid
as eluting agent. 16.0 g of the 2-(2-hydroxyethoxy)-ethyl ester of N-(3-
trifluoromethylphenyl)-anthranilic acid are obtained in the form of a pale
yellow oil which does not crystallize and cannot be distilled. | | Therapeutic Function | Antiinflammatory |
| | Etofenamate Preparation Products And Raw materials |
|
